Evotec and Ono extend research agreement
Sign a new agreement to study potential drug compounds
Evotec and Ono Pharmaceutical have extended their research collaboration and have signed a new agreement to study potential drug compounds.
Under the terms of the agreement, Evotec of Germany will provide high throughput screening, medicinal chemistry and in vitro pharmacology to discover novel, small molecular weight compounds active against an ion channel target selected by Japanese pharmaceutical company Ono. Ono will access Evotec's ion channel drug discovery platform and expertise. Evotec will receive research funding and milestone payments for its research services.
Evotec and Ono began their collaboration in March 2008 to identify novel inhibitors for a protease target. Within this collaboration Evotec provides protein crystallography, medicinal chemistry, biology and ADMET services to Ono with the aim of progressing a compound towards clinical development.
"We anticipate the collaboration will result in identifying a novel drug candidate with a high potential," said Kazuhito Kawabata, managing director of research headquarters at Ono.
